Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.

Samsung Biologics Co.,Ltd.

207940

Rangering i aksjer #498
Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon,... Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon, South Korea, provides contract services for biopharmaceutical products. The company's operations are divided into two main segments: Contract Manufacturing Organization (CMO) and Contract Development Organization (CDO). Its CDO services cover areas such as cell line development, optimization of upstream and downstream processes, and the formulation of analytical methods and final products. For CMO, the company offers aseptic filling, lyophilization, finishing, storage, shipping, and various associated support services. Additionally, it delivers comprehensive quality assurance, quality control, biosafety, and analytical testing. Samsung Biologics is also involved in creating and launching biosimilar drugs, alongside manufacturing mammalian cell-based antibody medications.
Aksjekurs
$1,028.49
Markedsverdi
$47.88B
Endring (1 dag)
-3.67%
Endring (1 år)
-18.37%
Land
KR
Handel Samsung Biologics Co.,Ltd. (207940)

Kategori

Healthcare
P/B-forhold for Samsung Biologics Co.,Ltd. (207940)
P/B-forhold per October 2026 TTM: 7.59
Ifølge Samsung Biologics Co.,Ltd. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 7.59. Ved slutten av 2024 hadde selskapet et P/B-forhold på 6.19.
P/B-historikk for Samsung Biologics Co.,Ltd. fra 2014 til 2026
P/B-forhold ved hvert års slutt
År P/B-forhold Endre
2026 (TTM) 7.59 -27.89%
2025 10.52 69.82%
2024 6.19 8.43%
2023 5.71 -11.02%
2022 6.42 -46.93%
2021 12.10 0.73%
2020 12.01 80.63%
2019 6.65 10.48%
2018 6.02 -8.12%
2017 6.55 197.83%
2016 2.20 -43.49%
2015 3.89 -78.44%
2014 18.05 0.00%
P/B-forhold for lignende selskaper eller konkurrenter
Selskap P/B-forhold Forskjell i P/B-forhold Land
6.6964 -11.72%
US
13.6307 79.69%
US
4.4521 -41.31%
AU
4.2241 -44.31%
BE
6.3632 -16.11%
NL